NVO

Novo-Nordisk A/S New York Stock Exchange
$82.31
Open: $82.12 High: $82.89 Low: $81.65 Close: $82.259
Range: 2021-06-23 - 2021-06-24
Volume: 768,849
Market: Open
Powered by Finage Stock APIDelayed data
NVO
Novo-Nordisk A/S Novo Alle Bagsværd , 2880 http://www.novonordisk.com
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.
  • CEO: Lars Fruergaard Jorgensen
  • Employees: 43,161
  • Sector: Healthcare
  • Industry: Biotechnology
NVO News
Latest news about the NVO
  • Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 21 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginnin

    View More →
  • Here's Why Altimmune Stock Is Surging Today

    Shares of Altimmune (NASDAQ: ALT), a clinical-stage biopharmaceutical company, are on the move following a positive clinical readout. Investors excited about the company's potential new weight loss drug drove the stock 23% higher as of 12:34 p.m. on Wednesday. Altimmune's weight loss drug candidate, ALT-801, is a GLP-1 receptor agonist that also activates glucagon receptors.

    View More →
  • The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric

    The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric

    View More →
  • Top Analyst Reports for Microsoft, Nike & Novo Nordisk

    Top Analyst Reports for Microsoft, Nike & Novo Nordisk

    View More →
  • Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates

    FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.

    View More →
  • Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity

    Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.

    View More →
  • Novo Nordisk's Semaglutide Gets FDA Approval to Tackle Obesity

    Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management. The drug will be available to obese adults and certain overweight people and should be used in conjunction with diet and exercise, Novo Nordisk said in a statement. Wegovy is the first weight management drug approved for chronic use in most obese and overweight adults since 2014, the FDA said. The medication will carry a warning about the risk of cer

    View More →
  • UPDATE 1-Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says

    Novo Nordisk's new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity treatment Saxenda in the United States, the firm said on Monday. A 2.4 milligram dosage of Novo Nordisk's semaglutide drug was approved by the U.S. Food and Drug Administration (FDA) on Friday under the name Wegovy, and will be launched on June 10.

    View More →
  • Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says

    Denmark's Novo Nordisk on Monday said that its recently approved obesity drug Wegovy could eat into sales of its existing obesity drug Saxenda, in the United States. "There is of course a risk of some cannibalisation between Wegovy and Saxenda and lower initial value per script, while we build the access for Wegovy," Novo's executive vice president of commercial strategy, Camilla Sylvest, told an investor briefing on Monday. "Our focus is to start new patients on Wegovy rather than switching patients currently benefiting from Saxenda," Sylvest added.

    View More →
  • FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%

    Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S.

    View More →
  • UPDATE 2-U.S. FDA approves Novo Nordisk's semaglutide as obesity treatment

    The U.S. Food and Drug Administration (FDA) on Friday approved Danish drugmaker Novo Nordisk's once-weekly semaglutide drug as a treatment for obesity, a condition that affects nearly 70% of American adults. The regulatory nod is a big win for Novo, which has seen its core insulin business suffer from tough competition, prompting it to turn toward newer diabetes and obesity drugs to revive growth. Novo's revenue growth has been driven by sales of its newer GLP-1 products, which imitate an intestinal hormone that stimulates insulin production, lowers appetite and increases feelings of fullness in patients.

    View More →
  • Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US

    Bagsværd, Denmark, 4 June 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy™ is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity. Wegovy™ is the first and only once-weekly glucagon-l

    View More →
  • 15 Most Valuable Pharmaceutical Companies In The World

    In this article we are going to list the 15 most valuable pharmaceutical companies in the world. Click to skip ahead and jump to the 5 most valuable pharmaceutical companies in the world. There is no denying the impact that the global pharma industry has had in the world, and probably been responsible for the […]

    View More →
  • Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment

    Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.

    View More →
  • Is Novo Nordisk A/S (NVO) A Smart Long-Term Buy?

    LRT Capital Management, an investment management firm, published its first-quarter 2021 investor letter – a copy of which can be downloaded here. A net return of +5.12%% was recorded by the LRT Economic Moat strategy for the Q1 of 2021, while the LRT Market Neutral strategy returned +2.4% for the same period. You can view the […]

    View More →
  • Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval

    Bagsværd, Denmark, 28 May 2021 – Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. The resubmission follows the Refusal to File letter received by the FDA on 22 March 2021. The standard review time by the FDA is 10 months. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com Company announcement No 36 / 2021 Attachment PR210528_Sustain_Forte_refiling

    View More →
  • The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Deere, BHP Group and Manulife Financial

    The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Deere, BHP Group and Manulife Financial

    View More →
  • Top Research Reports for Novo Nordisk, IBM, & Deere

    Top Research Reports for Novo Nordisk, IBM, & Deere

    View More →
  • Why Novo Nordisk Is Still a Top Stock for 2021

    Danish multinational pharmaceutical company Novo Nordisk (NYSE: NVO) is a quintessential blue-chip stock. Thanks to its very extensive portfolio of insulin drugs and diabetes-related products, it's held its own against companies like Eli Lilly, Abbott Labs, and Medtronic. Novo Nordisk reported Q1 earnings on May 4 along with a slew of other pharmaceutical companies including Bristol Myers Squibb, AbbVie, and Pfizer.

    View More →
  • Novo Nordisk, Eli Lilly Obesity Drugs Could Be Game Changers

    Medications in a new class of drug that seem to offer substantial advantages over current treatments

    View More →